黛力新联合思连康治疗中学生腹泻型肠易激综合征的临床研究

目的：观察黛力新联合思连康（口服双歧杆菌、乳杆菌、肠球菌、蜡样芽孢杆菌四联活菌片）治疗中学生肠易激综合征的疗效和安全性。方法：选择2007年10月2009年5月在我院消化科门诊符合罗马Ⅱ诊断标准的IBS患者,筛出频繁多次就诊（近4周内至少主动就诊3次以上）的中学生腹泻型肠易激综合征患者65例,随机分为两组。根据自愿的原则,采用自身对照研究,其中30例选择黛力新联合思连康治疗作为治疗组,35例选择思连康治疗作为对照组,疗程均为4周,比较药物疗效和安全性。结果：联合治疗组总有效率93.3%,单用思连康组总有效率60.0%,联合治疗组总有效率明显优于单用思连康对照组（P〈0.05）,两组患者均未发现明显的不良反应。结论：黛力新联合思连康治疗中学生腹泻型肠易激综合征安全、有效。

Clinical Study of the Effect and Safety of Combination of Deanxit with Siliankang in the Treatment for Students with Diarrhea-Predominant Irritable Bowel Syndrome

Objective：To observe the effect and safety of Deanxit in combination with Siliankang（Combined Bifidobacterium,Lactobacillus,Enterococcus and Bacillus cereus Tablets（Live）,Oral） in treatment for students with diarrhea-predominant irritable bowel syndrome（D-IBS）.Methods： 65 patients with refractory D-IBS were recruited into the randomized and open-label trial.According to patients＇selection,30 patients with D-IBS（Rome Ⅱ criteria） were enrolled in a self-control study on combination of Deanxit with Siliankang therapy for 4 weeks,and 35 patients with D-IBS in a self-control study on the Siliankang therapy for 4 weeks.All patients were diagnosed and treated in the Erdos Central Hospital,between October 2007 and May 2009.Results： The total effective rate was 93.3% in combination treatment group,and 60.0% in control group.The total effective rate in combination treatment group was significantly higher than that of control group（P〈0.05）.There were no obvious side-effects found in both groups.Conclusion： Deanxit combined with Siliankang is safe and effective in treatment of the students with DIBS.